{"name":"Jiangsu vcare pharmaceutical technology co., LTD","slug":"jiangsu-vcare-pharmaceutical-technology-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"VC005","genericName":"VC005","slug":"vc005","indication":"Type 2 diabetes","status":"phase_3"},{"name":"VC004 Capsules","genericName":"VC004 Capsules","slug":"vc004-capsules","indication":"Type 2 diabetes","status":"phase_3"},{"name":"VC005 Tablets","genericName":"VC005 Tablets","slug":"vc005-tablets","indication":"Type 2 diabetes","status":"phase_3"},{"name":"VC005 high dose group","genericName":"VC005 high dose group","slug":"vc005-high-dose-group","indication":"Type 2 diabetes","status":"phase_3"},{"name":"VC005 low dose group","genericName":"VC005 low dose group","slug":"vc005-low-dose-group","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Vicagrel","genericName":"Vicagrel","slug":"vicagrel","indication":"Other","status":"phase_3"},{"name":"Vicagrel and omeprazole","genericName":"Vicagrel and omeprazole","slug":"vicagrel-and-omeprazole","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"VC005","genericName":"VC005","slug":"vc005","phase":"phase_3","mechanism":"VC005 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"VC004 Capsules","genericName":"VC004 Capsules","slug":"vc004-capsules","phase":"phase_3","mechanism":"VC004 Capsules is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"VC005 Tablets","genericName":"VC005 Tablets","slug":"vc005-tablets","phase":"phase_3","mechanism":"VC005 Tablets is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"VC005 high dose group","genericName":"VC005 high dose group","slug":"vc005-high-dose-group","phase":"phase_3","mechanism":"VC005 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"VC005 low dose group","genericName":"VC005 low dose group","slug":"vc005-low-dose-group","phase":"phase_3","mechanism":"VC005 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Vicagrel","genericName":"Vicagrel","slug":"vicagrel","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Vicagrel and omeprazole","genericName":"Vicagrel and omeprazole","slug":"vicagrel-and-omeprazole","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPMHpITkR5enRaOGh0YlREQmxkUDdKOER2LUZUNnFjbGdEbC0zMUp5ODE4QjU0SVF5M3pac0dmUjE2UGg1a3ZKM281VDQyaTRmRTQ1X3dNanFOa2JNLW1iWGJ1c21uNDRyZG8xQ1daTmMtd0lwekZCTkQzZVpkUHE4dG1RLU55MDZMNmNPV0lrLW43ZEZ1OG12ekV1VnYyVEpKcE5LYmhLdnVQbV9JOXd3cnlCVS13OXJGeWp3OGo3MA?oc=5","date":"2026-03-17","type":"pipeline","source":"Nasdaq","summary":"Epidermolysis Bullosa Market Set for Significant Upswing During the Forecast Period (2025-2034) Amid Rising Therapeutic Advancements | DelveInsight - Nasdaq","headline":"Epidermolysis Bullosa Market Set for Significant Upswing During the Forecast Period (2025-2034) Amid Rising Therapeutic ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPd2p4RHowNHR3Y3VRTVJRLXE4VnhTN2hZZFBBUGV4RjFsUXp0UlZXQ3d4V2hyM2xFM1FEeWx2Z1FaTWVBV2k5SjVneGVGbVg3cFowMzlwRklPMDZSS01pTWJiQUE5TkRqcUN5emdzSjdXUnFwZlB1ZG80cllvdGpUMTBYenRWN0EtV1VWUUlnbDV6VVdBTlNWcg?oc=5","date":"2026-02-16","type":"pipeline","source":"Financial Times","summary":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight – Company Announcement - FT.com - Financial Times","headline":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxPZEoyWlFESV9na0VWS2Q1Z2FWMFlrS002cXFUMl9zakVKUXR0RDVfRmI3SUMtVUJzVlNiM2VwUEdwczUxMFkyZ3N2eDN2VTRxdEhzcUE5UkVjOTlfcmEyemo3OEFkblgteXo4RjFSNWR1R2hOUExkbWF3UnZ5Mm4xWk1qdWtyZHp3QTVEa1NyV3FXUWd4THBzX1NTVWNnSzBtaTY4ZC14Tnp6Z0ZkSUpFMVlmWnhiRjhKdV9oTEhVdVhkWVlCbTdKV2ZjcVV0UHFMVUE0MkxqNG1vYUtUSzJTM1hTNDFHR01McjI4Z3h2eEFzMFo4cThlR2VBTnA0cW1KSFJremNGWUN6cjJJUGpKNlpwcWVzNl91aEZDV0FnOA?oc=5","date":"2025-08-15","type":"deal","source":"PR Newswire","summary":"Vcare Enters into Exclusive Partnership with Huadong Medicine to Commercialize its second-generation JAK1 inhibitor, VC005 tablets, in China - PR Newswire","headline":"Vcare Enters into Exclusive Partnership with Huadong Medicine to Commercialize its second-generation JAK1 inhibitor, VC0","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQd3FBTE9tSFhFOG1MMTJyZDNuSFc4aHdYY1paY0RYN0pGdXdKZF9KMG9XdWJoS3d6QnFjTVF3QUhBTjZYcEV6TEdrUUREcjF0Sjk0TTIwbzF3UDN3bk9BNmpPSGh1bEhRMmJRTUxJM0s0T3lKeEFTcVFGSVVqbTVoT1EzbzhpdVhzOUtldW8wTmtUdw?oc=5","date":"2025-05-20","type":"trial","source":"Yahoo Finance","summary":"Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - Yahoo Finance","headline":"Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxQTGNjSHNvSG43RDVXd2V2bWt1MWM0cnFuTmV0bW45US1yb2R6c1d5OVZtWmRVODgxV2Q1c25CMDFFaE5XOHJrem53NjhBRXBQMVpKU0psa2VqU0MzYnhSdFlhTkFzRjNaZDhFWjVDYTlGTzVCSnBjZks3b2FjQlUtOXRwZmJWTHZyMUFrSWVwVG5rOW9WVEtnYW8zel9iTE8xcE85NWpHdGRMdTFHSWpCOGhYdkZWZGhJanlyNHBhcUx3RWpQZTN1bWYwNzJGUzRGSmpHd2k4dHo0MzdvR1pZblBjNzBBTG5scVZxWldJUQ?oc=5","date":"2025-01-15","type":"pipeline","source":"PR Newswire","summary":"Acute Coronary Syndrome Market to Showcase a Significant Growth at a CAGR of 7.7% by 2034 | DelveInsight - PR Newswire","headline":"Acute Coronary Syndrome Market to Showcase a Significant Growth at a CAGR of 7.7% by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQQ3JsSUFIYjk2LTNHU3Q3LVhzLUFNYmpFVUdTa2tPcGtpQ2NWQTFfaUxZYlZHbVJSWjVYSVBEZEVuQkdjN2tsWGhiRU1rOVhpLV9qR0pnTjlyWHJQVUgzVmlCbFcyZTM0YTJEbU5lTUMxZ0s1YUlJYVBqdmlwM2YxVkFrcHpMNkt1X0E?oc=5","date":"2024-01-04","type":"regulatory","source":"BioSpace","summary":"Jiangsu Vcare Files NDA for Vicagrel Capsules with US FDA - BioSpace","headline":"Jiangsu Vcare Files NDA for Vicagrel Capsules with US FDA","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_3":6,"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}